Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
inflammatory diseases
Pharma
Alfasigma's JAK inhibitor Jyseleca scores in phase 3 trial
Alfasigma has presented results from a phase 3 trial of Jyseleca, which has shown promise as a treatment for active axial spondyloarthritis.
Kevin Dunleavy
Jul 29, 2025 8:50am
InflaRx scraps vilobelimab study in rare skin disorder
May 28, 2025 9:55am
JPM25: Incyte plans to turn 'a lot of cards' in 2025, CEO says
Jan 22, 2025 2:38pm
Novartis rides IgAN trioka to trial wins in rare kidney diseases
May 28, 2024 11:20am
Takeda snags FDA nod for once-snubbed Eohilia to go after Sanofi
Feb 12, 2024 11:18am
Delayed FDA nod moves Lilly into crowded ulcerative colitis field
Oct 27, 2023 11:10am
